Hemodialysis reduces plasma apolipoprotein C-I concentration making VLDL a better substrate for lipoprotein lipase

Kidney International

Volumn 72, Issue 7, 2007, Pages 871-878

  Dautin, G ^a,b   Soltani, Z ^c   Ducloux, D ^d   Gautier, T ^a,b   Pais De Barros, J P ^a,b   Gambert, P ^a,b   Lagrost, L ^a,b   Masson, D ^a,b  

^a Institut Médical de Génétique et d Immunologie   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c HÔPITAL DU BOCAGE   (France)

^d HÔPITAL SAINT JACQUES   (France)

Author keywords

Apolipoprotein C I; Cholesteryl ester transfer protein; Hemodialysis; Lipoprotein lipase

Indexed keywords

APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN TRANSPORT;

AGED; APOLIPOPROTEIN C-I; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 34648828686     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002449     Document Type: Article

References (37)

1. Prichard S. Risk factors for coronary artery disease in patients with renal failure. Am J Med Sci 2003; 325: 209-213.
2. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
3. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
4. Reade V, Mezdour H, Reade R et al. Neutral-lipid transfers and cholesteryl ester transfer protein in hemodialyzed patients. Am J Nephrol 1996; 16: 394-401.
5. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003; 14: S315-S320.
6. Attman PO, Samuelsson O, Johansson AC et al. Dialysis modalities and dyslipidemia. Kidney Int 2003; 84(suppl): S110-S112.
7. Koniger M, Quaschning T, Wanner C, Schollmeyer P, Kramer-Guth A. Abnormalities in lipoprotein metabolism in hemodialysis patients. Kidney Int Suppl 1999; 71: S248-S250.
8. Chan MK, Persaud JW, Varghese Z, Moorhead JF. Post-heparin hepatic and lipoprotein lipase activities in nephrotic syndrome. Aust N Z J Med 1984; 14: 841-847.
9. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest 2003; 63: 45-53.
10. Schrader J, Andersson LO, Armstrong VW et al. Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis. Semin Thromb Hemost 1990; 16(Suppl): 41-45.
11. Nasstrom B, Stegmayr B, Gupta J et al. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrol Dial Transplant 2005; 20: 1172-1179.
12. Serdyuk AP, Morton RE. Lipid transfer inhibitor protein activity deficiency in normolipidemic uremic patients on continuous ambulatory peritoneal dialysis. Arterioscler Thromb Vasc Biol 1997; 17: 1716-1724.
13. Hirano T, Sakaue T, Misaki A et al. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int 2003; 63: 2171-2177.
14. Arnadottir M, Dallongeville J, Fruchart JC et al. Very-low-density lipoprotein of uremic patients is a poor substrate for bovine lipoprotein lipase in vitro. Metabolism 1996; 45: 686-690.
15. Weisgraber KH, Mahley RW, Kowal RC et al. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem 1990; 265: 22453-22459.
16. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 1991; 266: 18259-18267.
17. Soutar AK, Garner CW, Baker HN et al. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry 1975; 14: 3057-3064.
18. Soutar AK, Sigler GF, Smith LC et al. Lecithin:cholesterol acyltransferase activation and lipid binding by synthetic fragments of apolipoprotein C-I. Scand J Clin Lab Invest Suppl 1978; 150: 53-58.
19. Poensgen J. Apolipoprotein C-1 inhibits the hydrolysis by phospholipase A2 of phospholipids in liposomes and cell membranes. Biochim Biophys Acta 1990; 1042: 188-192.
20. Gautier T, Masson D, de Barros JP et al. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J Biol Chem 2000; 275: 37504-37509.
21. Conde-Knape K, Bensadoun A, Sobel JH et al. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. J Lipid Res 2002; 43: 2136-2145.
22. Berbee JF, Van der Hoogt CC, Sundararaman D et al. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J Lipid Res 2005; 46: 297-306.
23. Fojo SS, Brewer HB. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med 1992; 231: 669-677.
24. Boyle KE, Phillips MC, Lund-Katz S. Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochim Biophys Acta 1999; 1430: 302-312.
25. Randoux C, Gillery P, Georges N et al. Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes. Kidney Int 2001; 60: 1571-1577.
26. Mann H, Melzer H, Al-Bashir A et al. Testing protein permeability of dialysis membranes using SDS-PAGE. Int J Artif Organs 2002; 25: 441-446.
27. Moachon N, Boullange C, Fraud S et al. Influence of the charge of low molecular weight proteins on their efficacy of filtration and/or adsorption on dialysis membranes with different intrinsic properties. Biomaterials 2002; 23: 651-658.
28. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001; 12: 297-304.
29. Ishikawa I, Chikazawa Y, Sato K et al. Proteomic analysis of serum, outflow dialysate and adsorbed protein onto dialysis membranes (polysulfone and PMMA) during hemodialysis treatment using SELDI-TOF-MS. Am J Nephrol 2006; 26: 372-380.
30. Marsh JB, Welty FK, Schaefer EJ. Stable isotope turnover of apolipoproteins of high-density lipoproteins in humans. Curr Opin Lipidol 2000; 11: 261-266.
31. Marsh JB, Welty FK, Lichtenstein AH et al. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002; 162: 227-244.
32. Murdoch SJ, Breckenridge WC. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Atherosclerosis 1995; 118: 193-212.
33. Dumont L, Gautier T, De Barros JP et al. Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI. J Biol Chem 2005; 280: 38108-38116.
34. Lee DM, Knight-Gibson C, Samuelsson O et al. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002; 61: 209-218.
35. Mendez A, Perez GO, Goldberg RB, Hsia SL. Lipid and lipoprotein levels in undialyzed patients with chronic renal failure. Am J Med Sci 1987; 293: 164-170.
36. Dedecjus M, Masson D, Gautier T et al. Low cholesteryl ester transfer protein (CETP) concentration but normal CETP activity in serum from patients with short-term hypothyroidism Lack of relationship to lipoprotein abnormalities. Clin Endocrinol (Oxford) 2003; 58: 581-588.
37. de Man FH, De Beer F, Van de Laarse A et al. Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase. Atherosclerosis 1998; 136: 255-262.